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Abstract
Background: Chromium picolinate (Cr(pic)3) is advocated as adjuvant therapy for impaired
glycemic control, despite concerns for DNA damage. Potential toxicity of Cr(pic)3 should be
greater for the kidney that accumulates chromium. Therefore, we tested the hypothesis that
Cr(pic)3 treatment of obese Zucker rats (OZR) exacerbates renal abnormalities associated with
dysglycemia.
Methods: Male OZR were treated with diets lacking or containing 5 and 10 mg/kg of chromium,
as Cr(pic)3, for 20 weeks; lean Zucker rats (LZR) served as controls. Glycemic and renal effects of
Cr(pic)3 were determined in the context of indices of oxidative stress and inflammation.
Results: The OZR displayed increased fasting plasma glucose and insulin in association with
enlarged pancreatic islets exhibiting collagen and periodic acid Schiff-positive deposits compared to
LZR; Cr(pic)3 treatment did not affect these parameters. The OZR, irrespective of Cr(pic)3,
excreted more albumin than LZR. Also, other indices of renal function or histopathology were not
affected by Cr(pic)3 treatment. Urinary excretion of 8-hydroxydeoxyguanosine (8-OHdG), an
index of oxidative DNA damage, was greater in the OZR than LZR; dietary Cr(pic)3 treatment
attenuated 8-OHdG excretion. However, immunostaining of kidney for 8-OHdG revealed similar
staining pattern and intensity, despite significant renal accumulation of chromium in Cr(pic)3-
treated groups. Finally, increased renal nitrotyrosine and cyclooxygenase-2 levels and urinary
excretion of monocyte chemoattractant protein-1 of OZR were partially reversed by Cr(pic)3
treatment.
Conclusion: Dietary Cr(pic)3 treatment of OZR does not beneficially influence glycemic status or
increase the risk for oxidative DNA damage; rather, the treatment attenuates indices of oxidative
stress and inflammation.
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Introduction
The worldwide epidemic of obesity is a major predispos-
ing factor for the ever increasing prevalence and incidence
of glucose intolerance and type 2 diabetes [1,2]. In turn,
obesity and impaired glucose tolerance/type 2 diabetes
markedly increase the risk for development of renal and
cardiovascular complications [3,4]. Further, obesity is
known as a pro-inflammatory state thereby contributing
importantly to eventual target organ manifestations and
associated morbidity and mortality [5,6].
Of various animal models of obesity and type 2 diabetes
mellitus, the obese Zucker rats (OZR) have been used
extensively for studies focused on consequences of the dis-
ease and the contributing mechanisms. The OZR have an
autosomal recessive mutation of the fa gene encoding the
leptin receptor. The OZR display marked obesity, dyslipi-
demia, severe insulin resistance, increased oxidative stress
and a proinflammatory state compared to the lean Zucker
rats (LZR) [7-9]. Thus, the OZR can serve as a useful ani-
mal model for determination of potential influences of
therapies aimed at prevention or attenuation of obesity/
type 2 diabetes-related abnormalities.
The nutritional supplement, chromium picolinate
(Cr(pic)3), contains trivalent chromium which is chelated
to three picolinic acid molecules to increase its bioavaila-
bility compared to non-chelated forms (e.g., chromium
chloride). It is widely used because of claims that it exerts
antidiabetic and weight-reduction effects [10-12].
Improvement in glycemic status, in turn, should reduce
oxidative stress and the proinflammatory conditions asso-
ciated with obesity/type 2 diabetes thereby ameliorating
target organ complications such as nephropathy. On the
other hand, other studies have raised concerns regarding
the safety of Cr(pic)3 as they indicate that the formulation
increases the risk for DNA damage [13-16]. If indeed the
formulation exerts adverse effects in vivo, its potential tox-
icity would be expected to be more prominent for the kid-
ney which serves not only as its major route of
elimination but also accumulates chromium [17-19].
Thus, long-term effects of the formulation need to be
established utilizing animal models of the disease for
which its use is advocated. Therefore, we tested the
hypothesis that, despite improvement in glycemic status,
chronic treatment of OZR with Cr(pic)3 causes significant
renal accumulation of chromium with adverse conse-
quences for kidney function and structure. Accordingly,
renal effects of the chromium formulation were deter-
mined in the context of indices of oxidative stress (e.g., tis-
sue nitrotyrosine), inflammation (e.g., urinary excretion
of monocyte chemoattractant protein-1 (MCP-1), renal
expression of cyclooxygenase-2 and tissue CD68 positive
histiocytes) and oxidative DNA damage (e.g., urinary
excretion and tissue 8-hydroxydeoxyguanosine (8-
OHdG)).
Methods and materials
Male obese and lean Zucker rats (OZR and LZR, respec-
tively) were obtained form Harlan Laboratories at about 6
weeks of age. The animals were housed in the laboratory
animal facilities at the Medical College of Georgia that are
controlled for humidity (60% ± 5%), temperature (24° ±
1°C) and light cycle (6 AM to 6 PM). Two days after
arrival, the OZR were randomly assigned to either remain
on the regular rodent diet (Harlan Teklad diet number
8604) or switched to the 8604-based diet that was supple-
mented with 5 or 10 mg/kg of chromium as Cr(pic)3 (i.e.,
OZR; 5 Cr and OZR; 10 Cr, respectively; Harlan Teklad
diet numbers 07602 and 07603, respectively; n = 10 ani-
mals per group); LZR (n = 10) were provided with the
8604 diet (without supplemental chromium). One
untreated OZR and one OZR; 5 Cr died before terminal
measurements at about 26 weeks of age. Unless otherwise
specified, the animals had free access to food and water
throughout the studies. Based on measurement of food
intake, the 5 and 10 mg/kg chromium diets provided
chromium at doses of 0.19 ± 0.02 and 0.41 ± 0.02 mg/kg/
day (or 1.58 ± 0.16 and 3.29 ± 0.12 mg/kg/day of
Cr(pic)3, respectively); the chromium intake in this study
is similar to other studies utilizing rodents [20-22]. The
use of animals for these studies conformed to the institu-
tional guidelines for the care and use of laboratory ani-
mals.
At about 26 weeks of age, tail-cuff hemodynamics were
measured and two consecutive 24-hour urine samples col-
lected from each animal; urine samples were used for
determination of urinary electrolytes, albumin, 8-OHdG
and MCP-1 excretions. Further, hemoglobin A1c levels
were measured using a drop of blood from the tail (Bayer
HealthCare - Diabetes Care, Sunnyvale, California). For
determination of plasma glucose and insulin concentra-
tions, the animals were fasted overnight and blood sam-
ples were obtained from the tail. Plasma glucose
concentration was measured using a Beckman glucose
analyzer. On the other hand, plasma insulin concentra-
tion was measured using an insulin 125I radioimmu-
noassay Kit (MP Biomedicals, LLC; Solon, OH). The data
were used to calculate the insulin resistance Homeostatic
Model Assessment (HOMA) index as follows: (FPI ×
FPG)/22.5 where FPI and FPG denote fasting plasma insu-
lin (μU/ml) and fasting plasma glucose (mmol/l), respec-
tively [23].
After collection of metabolic data and measurement of
systemic hemodynamics, the animals were anesthetized
with sodium pentobarbital (45-50 mg/kg; i.p.) and renal
tissue procured for histopathological (i.e., 10% formalin-Nutrition & Metabolism 2009, 6:51 http://www.nutritionandmetabolism.com/content/6/1/51
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fixed), Western and slot blot analyses (frozen in liquid
nitrogen) and chromium measurement (air-dried). Also,
the pancreas was fixed in buffered formalin for his-
topathological examination.
Formalin-fixed and paraffin-embedded tissue (i.e., kidney
or pancreas) blocks were cut in 5 μm sections followed by
staining (e.g., hematoxylin-eosin (H&E), Masson Tri-
chrome or periodic acid Schiff (PAS)); frozen sections
were used for Oil-Red-O staining [8]. Immunohistochem-
ical staining was carried out utilizing mouse anti- 8-
OHdG primary antibody (Oxis Research, Foster City, CA)
and biotinylated goat anti-mouse secondary antibody
(Vector Labs, Burlingame CA).
Western and slot blot analysis
To determine renal cyclooxygenase-2 (COX-2) and nitro-
tyrosine levels, frozen renal tissue was pulverized and
added to the isolation buffer (10 mM triethanolamine,
250 mM sucrose, PH 7.6, 1 μg/ml leupeptin, PMSF (2 mg/
ml), sonicated and sodium dodecyl sulfate added to a
final concentration of 1% prior to centrifugation; the
supernatant was used for protein assay (Biorad protein
assay DC kit). Standard protocols were used for Western
blot analysis as described previously (i.e., 10% gels, elec-
trophoretic protein transfer to nitrocellulose membrane,
rabbit anti-COX-2 polyclonal antibody (Cayman, Ann
Arbor, Michigan), secondary antibody (goat anti-rabbit
IgG, Cell Signaling, Danvers, MA) and detection by
enhanced chemiluminescence) [24,25]. Slot-blot analysis
was used to measure the nitrative stress marker: nitrotyro-
sine. As described previously [26], samples were immobi-
lized onto a nitrocellulose membrane using Slot Blot
apparatus (BioRad). After blocking, membranes were
reacted with antibodies against nitrotyrosine (Calbio-
chem), followed by determination of optical density. The
COX-2 and nitrotyrosine data were corrected for β-actin
and expressed as percent of the LZR group.
Assays
Urinarysodium and potassium were measured (Easy Elec-
trolytes, Medica Corporations, Bedford, MA) and used to
calculate excretion rates. Urine osmolality was measured
by an osmometer. Urinary albumin excretion was meas-
ured using the Nephrat ELISA kit (Exocell, Philadelphia,
PA). Urinary and plasma creatinine were measured (Cay-
man Chemicals and Biovision, respectively) and used to
calculate creatinine clearance rate (an index of the glomer-
ular filtration rate). Urinary excretions of 8-OHdG and
MCP-1 were measured using ELISA kits [(Northwest Life
Science Specialties, LLC; Vancouver, WA) and (BD Bio-
science, San Jose, CA), respectively]. All parameters were
determined on two consecutive 24 hour urine samples
and average values recorded for each animal. Analysis of
kidney chromium content was carried out by the Wiscon-
sin State Laboratory of Hygiene using Inductively Cou-
pled Plasma Mass Spectrometry (ICP-MS) technology.
Statistics
All data were analyzed by the analysis of variance
(ANOVA). Duncan's post hoc test was used for compari-
son of mean values (significance of criteria of p < 0.05).
Data are reported as means ± SEM.
Results
Physical features
All rats displayed significant increase in body weight dur-
ing the course of the study although the OZR, irrespective
of Cr(pic)3 treatment, gained significantly more weight
than their lean controls (Figure 1A). As an index of skele-
tal growth, the length of femur and tibia were measured in
experimental groups. While obesity was associated with
slight reductions in the length of both the tibia and the
femur, Cr(pic)3 treatment, per se, did not influence these
parameters (Table 1). Kidney weight was greater in the
OZR, irrespective of dietary chromium treatment, than
LZR; however, kidney to body weight ratio was similar
among the groups (Table 1). Further, systolic blood pres-
sure, diastolic blood pressure and mean arterial pressure
were similar among the groups (Figure 1B). Also, no dif-
ferences were noted in heart rates among the groups (aver-
age of 462-485 beats/min).
Glycemic status
The OZR displayed greater fasting plasma glucose (about
30%) and plasma insulin (about 400%) concentrations
compared to their lean controls (Table 1). As a result, the
HOMA insulin-resistance index was markedly elevated in
the OZR, irrespective of Cr(pic)3 treatment, than LZR
(Table 1). On the other hand, hemoglobin A1c levels were
similar among the four experimental groups (Table 1).
Microscopic examination of LZR pancreas revealed well-
preserved pancreatic exocrine lobules consisting of
packed acinar units which are interspersed by sharply-
demarcated, small islets of Langerhans (Figure 2, panel
A). Cytologic and nuclear details were bland and uniform
in shape, size and staining characteristics. Microscopic
examination of pancreas for OZR, OZR; 5 Cr and OZR; 10
Cr groups revealed enlarged, hyperplastic islets of Langer-
hans (of varying sizes) exhibiting benign cellular prolifer-
ation which resulted in irregular and "jagged" peripheral
outline (Figure 2, panels B-D). The islet cellular elements
were separated by variable aggregates of extracellular
deposits; however, the sizes or cytologic and nuclear
details of pancreatic islets were generally similar among
the three groups of OZR. As shown in Figure 2, while there
was minimal staining of the LZR pancreas for PAS (panel
E), those of OZR groups (panels F-H), irrespective of
Cr(pic)3 treatment showed prominent patchy areas of
PAS-positive material. Similarly, trichrome-stained tissueNutrition & Metabolism 2009, 6:51 http://www.nutritionandmetabolism.com/content/6/1/51
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sections from LZR group revealed uniform well-preserved,
small collagen-free pancreatic islets (Panel 2, panel I). On
the other hand, Trichrome-stained tissue sections from
OZR, OZR; 5 Cr and OZR; 10 Cr groups revealed promi-
nent (and generally similar) intercellular deposits of col-
lagen fibers confined within hyperplastic pancreatic islets
(Figure 2, panels J-L). These histopathological findings are
consistent with the interpretation of islet hyperplasia with
interstitial fibrosis.
Kidney function and structure
The OZR tended to consume more water and excreted
more urine than their lean counterparts (Table 1). The
Cr(pic)3-treated OZR showed mild increases in water
intake and urine excretion. However, the ratio of urine
output to water intake was similar among the groups
(Table 1). Urine osmolality was similar between the LZR
and OZR rats irrespective of Cr(pic)3 treatment (Table 1).
The untreated OZR group showed a mild increase in daily
excretion of sodium and potassium (normalized to food
intake) than LZR; dietary Cr(pic)3 treatment did not affect
these parameters (Table 1). Also, creatinine clearance was
similar among the groups (Table 1). However, daily albu-
min excretion was greater in OZR, irrespective of Cr(pic)3
treatment, than LZR (Table 1).
Hematoxylin and eosin-stained sections from all groups
showed histopathologic changes with varying degrees of
intensity (Figure 3, panels A-D). Microscopic examination
of tissue sections from LZR and OZR groups revealed his-
tomorphologic changes including tubular dilation, eosi-
nophilic protein casts and minimal interstitial chronic
inflammation in 60% vs. 100% of LZR and OZR groups,
respectively. Tissue sections from OZR; 5 Cr group
showed changes in 75% of subjects with diffuse tubular
dilation, tubular protein casts, interstitial chronic inflam-
mation and cystic tubular formations. Tissue sections
from the OZR; 10 Cr group showed a mix of histologic
grades of intensity with pathologic changes in 80% of sub-
jects ranging from mild (40%) to moderate (20%) and
severe (40%; Figure 3D).
For further assessment of renal histopathology, PAS stain
was performed to evaluate deposits within the basal lam-
ina surrounding and within the mesangium of the
glomerular vascular tuft as well as the interstitial blood
vessels (Figure 3E-H). Sections were assigned "mild"
when there were focal intraglomerular deposits in 10% or
less of glomeruli or interstitial vessels. Sections were
assigned "moderate" when there were patchy intraglomer-
ular deposits or interstitial vessels in 20-50% of these
structures. Sections were assigned "severe" when there
were diffuse intraglomerular deposits and in interstitial
vessels involving > 50% of these structures. Sections from
LZR showed mild and focal intraglomerular deposits in
20% of subjects. Sections for OZR showed patchy moder-
ate PAS-positive intraglomerular deposits in 80% of sub-
jects. The OZR; 5 Cr group showed diffuse
Table 1: Physical and metabolic features of experimental groups.
LZR OZR OZR; 5 Cr OZR; 10 Cr
Femur length (mm) 37.5 ± 0.5* 33.7 ± 0.6 32.8 ± 0.3 32.6 ± 0.4
Tibia length (mm) 42.9 ± 0.3* 40.9 ± 0.2 40.3 ± 0.2 40.8 ± 0.4
Kidney weight (g) 3.44 ± 0.16* 4.74 ± 0.22 4.44 ± 0.2 5.28 ± 0.3
Kidney to body weight (mg/g) 7.04 ± 0.34 6.33 ± 0.21 6.10 ± 0.39 6.92 ± 0.39
Plasma glucose (mg/dl) 130.8 ± 5.0* 165.0 ± 8.9 175.0 ± 7.1 176.5 ± 5.5
Plasma insulin (μU/ml) 21.4 ± 1.5* 84.2 ± 4.6 73.3 ± 6.6 80.0 ± 9.9
HOMA index 8.1 ± 1.2* 33.8 ± 2.9 31.8 ± 3.3 34.2 ± 3.9
HgA1c (%) 4.6 ± 0.1 4.9 ± 0.1 4.6 ± 0.2 4.9 ± 0.1
Water intake (ml/day) 32.6 ± 0.7 38.7 ± 2.2 44.7 ± 3.8# 47.0 ± 3.1#
Food intake (g/day) 25.4 ± 1.3 29.7 ± 1.4 28.7 ± 2.9 31.2 ± 1.4
Urine excretion (ml/day) 17.6 ± 1.1 23.3 ± 2.1 28.4 ± 3.3# 28.3 ± 3.0#
Urine excretion to fluid intake ratio (%) 54.4 ± 3.0 62.0 ± 3.9 62.9 ± 3.4 59.6 ± 4.2
Urine Osmolality (mOsmol/kg) 1615 ± 72 1655 ± 96 1372 ± 128 1474 ± 102
Sodium excretion (μEq/g food/day) 78.3 ± 5.8 104 ± 10.8# 82.3 ± 4.4 97.1 ± 6.4
Potassium excretion (μEq/g food/day) 231 ± 16 315 ± 57.5 242 ± 13 227 ± 18.6
Creatinine clearance (ml/min) 0.66 ± 0.12 0.60 ± 0.06 0.72 ± 0.09 0.69 ± 0.08
Albumin excretion (mg/day) 41.4 ± 5.4* 70.4 ± 7.2 69.2 ± 7.4 61.6 ± 7.8
* p < 0.05 compared to other groups.
# p < 0.05 compared to the LZR group.Nutrition & Metabolism 2009, 6:51 http://www.nutritionandmetabolism.com/content/6/1/51
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intraglomerular PAS-positive deposits in 70% of subjects
while the OZR; 10 Cr group showed mild and patchy int-
raglomerular PAS-positive deposits in 75% of subjects.
We next performed Masson's trichrome stain on renal tis-
sue to help highlight glomerular or interstitial fibrosis.
Tissue sections from LZR and OZR groups did not show
trichrome-positive fibrotic changes. However, 60% of kid-
neys from the OZR; 5 Cr group and 80% of subjects from
the OZR;10 group showed few scattered patchy foci of
interstitial fibrosis (data not shown).
Oil-Red-O stain was performed to help reveal cellular fat
deposits. All groups showed the presence of fat droplets;
however, fat droplets were more numerous in the
untreated OZR group (Figure 3I-L, arrows).
Indices of nitrosative/oxidative stress and inflammation
Tissue nitrotyrosine is considered as a stable footprint of
oxidative stress. As shown in Figure 4, kidneys of OZR dis-
played greater accumulation of nitrotyrosine than those of
the LZR; chronic Cr(pic)3 treatment was associated with
attenuation of renal tissue nitrotyrosine levels thereby
eliminating a significant differential in comparison to the
LZR (Figure 4).
In order to determine whether chronic Cr(pic)3 treatment
increases whole body oxidative DNA damage, urinary
excretion of 8-OHdG was measured in the experimental
groups. As shown in Figure 5, the untreated OZR dis-
played greater urinary 8-OHdG excretion. The treatment
was associated with a decline in urinary 8-OHdG excre-
tion towards that of the LZR. Interestingly, however,
immunostaining of renal tissue for 8-OHdG did not
reveal differences in either the (nuclear) pattern or inten-
sity of staining among experimental groups (Figure 6A-
D); similar findings were noted for the pancreas (Figure
2M-P).
As indices of inflammation, urinary excretion of MCP-1,
immunostaining for tissue histiocytes (i.e., CD68 positive
cells) and renal tissue level of COX-2 were determined. As
shown in Figure 7, urinary excretion of MCP-1 was signif-
icantly higher in the OZR than LZR; Cr(pic)3 treatment
was associated with attenuation of urinary MCP-1 excre-
tion thereby eliminating the significant differential with
respect to the LZR group. Examination of renal tissues for
LZR group did not identify CD68 positive cells while
those of the OZR, irrespective of Cr(pic)3 treatment
showed generally similar foci of multiple CD68 positive
cells (Figure 6E-H). Similarly, renal expression of COX-2
was increased in the OZR than LZR; the higher Cr(pic)3
diet was associated with reduction in COX-2 level towards
that of the LZR group (Figure 8).
Chromium is known to accumulate in tissues including
the kidney. Therefore, to determine whether the OZR kid-
ney also accumulates chromium, renal tissue chromium
content was measured by ICP-MS. As shown in Figure 9,
renal tissue chromium content tended to be lower in the
OZR than LZR, an aspect that may relate to the require-
ment of cellular uptake of chromium for normal insulin
signaling [27]. As expected, dietary Cr(pic)3 treatment
resulted in a dose-related accumulation of chromium in
the OZR kidneys (Figure 9).
Discussion
The present study shows that long-term Cr(pic)3 treat-
ment does not influence abnormal glycemic status or
indices of growth of OZR. Further, the treatment is not
associated with exacerbated oxidative DNA damage.
Rather, the treatment exerts mild-moderate beneficial
Body weight and blood pressure Figure 1
Body weight and blood pressure. Panel A shows time-
course of changes in body weight while panel B shows blood 
pressure of lean Zucker rats (LZR), untreated obese Zucker 
rats (OZR) and OZR treated with diets containing 5 and 10 
mg/kg of chromium as Cr(pic)3 (i.e., OZR; 5 Cr and OZR; 10 
Cr, respectively). The treatments were initiated at 6 weeks 
of age (i.e., time 0). Data are means ± SEM of 9-10 animals/
group. * p < 0.05 compared to the other groups at the same 
time point.Nutrition & Metabolism 2009, 6:51 http://www.nutritionandmetabolism.com/content/6/1/51
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effects on several markers of oxidative stress and inflam-
mation in OZR.
The interest in chromium supplementation stems from
earlier studies that suggested an essential role for trivalent
chromium in carbohydrate and lipid metabolism
[10,17,28]. These studies showed that rats consuming a
diet lacking chromium developed an inability to effi-
ciently dispose of blood glucose [17,10]. This defect was
reversed by addition of chromium-enriched food or by
supplementation with synthetic trivalent chromium. Sub-
sequent observation that patients on total parenteral
nutrition also develop a deficit in carbohydrate metabo-
lism, which can be alleviated with trivalent chromium,
established the essential role of trivalent chromium in
human diet as well [17,10]. Although the exact molecular
events subserving the effect of chromium on glucose
metabolism remain to be established, a number of mech-
anisms have been proposed that collectively lead to
amplification of insulin signaling (e.g., increased insulin
receptor binding but inhibition of insulin receptor tyro-
sine phosphatase) [28,29]. In light of these reports, we
had expected that long-term Cr(pic)3 treatment of OZR
would improve insulin resistance. Surprisingly, however,
the treatment did not beneficially influence several indi-
ces of glycemic control or the marked histopathological
features of pancreatic islets in OZR. Nonetheless, the
results are consistent with a recent report indicating that
Pancreas histopathology Figure 2
Pancreas histopathology. Panels show representative H&E-stained sections (A-D; 100×), PAS-stained sections (E-H; 200×) 
and trichrome-stained section (I-L; 200×) of pancreas from experimental groups as described in Figure 1. Also shown is the 
immunohistochemical localization of 8-OHdG in pancreas of experimental groups (Panels M-P, 200×)Nutrition & Metabolism 2009, 6:51 http://www.nutritionandmetabolism.com/content/6/1/51
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Cr(pic)3, at a dose of 1000 μg/day, does not improve
insulin sensitivity or several other features of metabolic
syndrome in obese adults [30]. Human studies have typi-
cally used chromium at a dose of 200-1000 μg/kg [29-31].
Assuming an average body weight of 70 kg, this corre-
sponds to a range of about 3-14 μg/kg of chromium sup-
plementation. Animal studies, on the other hand, have
used dosages similar to (and even far higher than) the
ones used in this study (about 190 to 410 μg/kg/day for
OZR; 5 Cr and OZR; 10 Cr groups, respectively)
[22,29,31]. Thus, it is likely that far higher doses of the
formulation would be required to unmask a beneficial
effect on glycemic control in the setting of marked insulin
resistance as it occurs in OZR. Nonetheless, the results
raise question about the efficacy of Cr(pic)3, alone, in
doses that are commonly consumed by human subjects
although the possibility that such doses may exert addi-
tive or synergistic effects with physical exercise and/or
other interventional modalities remains to be explored.
This notion is consistent with a report indicating that
Cr(pic)3 supplementation increases insulin sensitivity
and improves glycemic status of type 2 diabetic patients
who are on sulfonylurea agents [32].
It is well-established that abnormal glycemic state of obes-
ity and diabetes mellitus are associated with increased oxi-
dative stress and subsequent oxidative DNA damage [3];
indeed, generation of 8-OHdG is considered as a surro-
gate marker of enhanced oxidative stress and associated
oxidative DNA damage [33]. Thus, we conjectured that
Cr(pic)3-induced improvement in glycemic control
should reduce 8-OHdG production. On the other hand, if
indeed Cr(pic)3 treatment increases oxidative DNA dam-
age, then the treatment should further increase 8-OHdG
generation in the setting of increased oxidative and nitro-
sative stress that are features of OZR [7]. Consistent with
Kidney histopathology Figure 3
Kidney histopathology. Panels A-D show representative H&E-stained while panels E-H show representative PAS-stained 
kidney sections from experimental groups as described in Figure 1 (100× and 200×, respectively). Also shown are representa-
tive panels for Oil-Red-O stained renal tissue from experimental groups (panels I-L, 200×; arrows point to lipid droplets).Nutrition & Metabolism 2009, 6:51 http://www.nutritionandmetabolism.com/content/6/1/51
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this notion, urinary excretion of 8-OHdG was signifi-
cantly higher in the OZR than LZR, suggesting an increase
in whole body oxidative stress. On the other hand, renal
tissue nitrotyrosine level was increased in kidneys of OZR
than LZR reflecting an increase in local oxidative/nitrosa-
tive stress. Interestingly, however, Cr(pic)3 treatment did
not increase either urinary excretion of 8-OHdG or renal
tissue nitrotyrosine content. Rather, the treatment was
associated with mild reductions in both parameters that
were sufficient enough to abrogate statistical significance
compared to the LZR group. Interestingly, the reductions
in 8-OHdG excretion and tissue nitrotyrosine level were
not associated with any improvement in glycemic status
of OZR. In this context, Chander and colleagues [7] have
shown that treatment of OZR with ebselen (an antioxi-
dant and peroxynitrite scavenger) reduces lipid peroxida-
tive products and 3-nitrotyrosine-modified proteins
without affecting blood glucose.
Since urinary excretion of 8-OHdG is a surrogate biomar-
ker of whole body oxidative DNA damage, we also carried
out immunohistochemical examination of the kidney for
8-OHdG. The rationale for this relates to the fact that tri-
valent chromium is known to accumulate in a number of
organs although the kidney accumulates it to a greater
extent [17-19]. Indeed, as shown in Figure 9, Cr(pic)3-
enriched diets caused significant increases in kidney chro-
mium content of the OZR. Thus, we conjectured that any
adverse effect of Cr(pic)3 treatment on oxidative DNA
damage should be more readily detected in the kidney.
Interestingly, however, immunostaining of renal tissue
did not reveal differential patterns or intensity among the
experimental groups; similar findings were noted for the
pancreas. These observations coupled with the demon-
stration that urinary excretion of 8-OHdG increases in
conditions associated with oxidative stress suggest that the
modified nucleoside is largely released rather than being
accumulated in the tissue(s). Nonetheless, immunostain-
ing findings and urinary excretion profile of 8-OHdG do
not support the notion that Cr(pic)3 enhances oxidative
DNA damage in OZR. As indicated earlier, a major con-
cern regarding Cr(pic)3 relates to reports of increased risk
of genotoxicity associated with its use [13-16]. Genotoxic-
ity of trivalent chromium has been shown in acellular sys-
tems where direct interaction occurs with the genetic
material [34,31,15]. However, trivalent chromium com-
pounds, including Cr(pic)3, have produced conflicting
results in ex vivo and in vivo studies likely due to multiple
reasons including low cellular uptake of trivalent chro-
mium and the demonstration that it does not avidly accu-
mulate in DNA containing organelles such as the nucleus
or the mitochondria [18,19]. The results of this study are
in agreement with this notion and the more recent reports
indicating lack of a significant DNA toxicity of Cr(pic)3
[20,35].
Consistent with other reports, the OZR displayed a
number of renal abnormalities compared to their lean
counterparts including greater albuminuria and his-
topathological changes indicative of extracellular matrix
deposits, inflammatory infiltrates and tubulointerestitial
injury. Nonetheless, renal tubular dilatations were noted
for both LZR and OZR thereby suggesting lack of a corre-
lation of this abnormality with metabolic derangements
associated with obesity and (or) type 2 diabetes. It is note-
worthy that there were numerous lipid droplets in renal
tissue of OZR than LZR; ectopic lipid accumulation is
believed to contribute importantly to pathophysiology of
Kidney nitrotyrosine content Figure 4
Kidney nitrotyrosine content. Bar graphs show renal tis-
sue nitrotyrosine level in experimental groups as described in 
Figure 1; data are expressed as percent of the LZR group. 
Also shown are representative blot for each group. Data are 
means ± SEM of 7-9 animals per group. * p < 0.05 compared 
to the LZR group.
Urinary excretion of 8-hydroxydeoxyguanosine (8-OHdG) in  experimental groups as described in Figure 1 Figure 5
Urinary excretion of 8-hydroxydeoxyguanosine (8-
OHdG) in experimental groups as described in Fig-
ure 1. Data are means ± SEM of 9-10 animals/group. * p < 
0.05 compared to the LZR or OZR;10 Cr groups.Nutrition & Metabolism 2009, 6:51 http://www.nutritionandmetabolism.com/content/6/1/51
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organ dysfunction in obesity/type 2 diabetes (i.e., lipotox-
icity) [36]. More importantly, however, it is suggested that
release of autocrine and paracrine factors from periorgan
fat deposits contributes importantly to the pathogenesis
of cardiac abnormalities in animals with dietary fat-
induced obesity [37]. Indeed, OZR display marked depos-
its of fat around the kidney, effectively encasing the organ.
Nonetheless, the contribution of autocrine and paracrine
release of factors from adipose tissue surrounding the kid-
ney, an encapsulated organ, to eventual manifestation of
renal pathology in OZR remains to be established. Impor-
tantly, however, Cr(pic)3 treatment did not result in sig-
nificant beneficial effects on renal function (e.g.,
albuminuria) or histopathological findings of OZR.
The lack of significant effects of Cr(pic)3 on renal function
and structure are seemingly inconsistent with its mild-
moderate ameliorating effects on indices of oxidative
stress (e.g., tissue nitrotyrosine) and inflammation (e.g.,
Kidney 8-OHdG and CD 68 immunostaining Figure 6
Kidney 8-OHdG and CD 68 immunostaining. Panels A-D show representative 8-OHdG-immunostained kidney sections 
from experimental groups while panels E-H show immunostaining for CD68 positive tissue histiocytes (200× except panel E 
which is shown at 100×).
Urinary excretion of MCP-1 in experimental groups as  described in Figure 1 Figure 7
Urinary excretion of MCP-1 in experimental groups 
as described in Figure 1. Data are means ± SEM of 9-10 
animals/group. * p < 0.05 compared to LZR group.
Renal expression of cyclooxygensae-2 for experimental  groups as described in Figure 1 Figure 8
Renal expression of cyclooxygensae-2 for experimen-
tal groups as described in Figure 1. Data are normalized 
to β-actin and expressed as percent of the LZR group. Data 
are means ± SEM of 7-9 animals per group. Also shown is 
representative blot for each group and its β-actin control. * p 
< 0.05 compared to the LZR or OZR; 10 Cr groups.Nutrition & Metabolism 2009, 6:51 http://www.nutritionandmetabolism.com/content/6/1/51
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urinary MCP-1 excretion and renal tissue COX-2 level).
However, it is important to note that multiple mecha-
nisms contribute to genesis of proteinuria and renal dys-
function associated with obesity and type 2 diabetes
including metabolic, hemodynamic (both systemic and
intrarenal), oxidative stress and a variety of inflammatory
cytokines and chemokines [3]. Ultimately, the net effect
of these changes results in loss of glomerular membrane
permeability barrier and albuminuria. It is noteworthy
that systemic hemodynamics and metabolic status of the
3 Cr(pic)3-treated OZR groups were generally similar
thereby suggestive of similar contribution of these deter-
minants to albuminuria. On the other hand, although the
parameters that were measured in this study are known to
contribute to genesis of proteinuria, it is likely that the
mild Cr(pic)3-induced changes in their levels are not suf-
ficient to beneficially influence albuminuria. Alterna-
tively, Cr(pic)3 in doses that were used in this study may
not be sufficient enough to alter the course and/or extent
of proteinuria.
In conclusion, long-term Cr(pic)3 intake in doses that
exceed those consumed by human subjects does not exert
beneficial effects on glycemic control or adversely affect
growth of OZR. In addition, despite renal accumulation of
chromium, kidney function and structure were generally
similar among untreated and treated OZR. Importantly,
the treatment did not increase either urinary excretion of
8-OHdG or its immunohistochemical pattern and inten-
sity in the kidney and the pancreas. Rather, Cr(pic)3 treat-
ment of OZR was associated with attenuations in indices
of oxidative stress and inflammation thereby diminishing
the differentials with LZR.
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